Announcement • Jun 04
Sabaa International Company for Pharmaceutical and Chemical Industry, Annual General Meeting, Jun 27, 2026 Sabaa International Company for Pharmaceutical and Chemical Industry, Annual General Meeting, Jun 27, 2026, at 13:00 Egypt Standard Time. Location: cairo Egypt Board Change • May 20
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • Jun 26
Sabaa International Company for Pharmaceutical and Chemical Industry, Annual General Meeting, Jul 28, 2025 Sabaa International Company for Pharmaceutical and Chemical Industry, Annual General Meeting, Jul 28, 2025, at 14:30 Egypt Standard Time. Location: cairo Egypt Board Change • May 14
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. New Risk • Sep 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Egyptian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (ج.م13m revenue, or US$264k). Market cap is less than US$10m (ج.م226.5m market cap, or US$4.68m). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change). Reported Earnings • Aug 31
Second quarter 2024 earnings released: ج.م0.17 loss per share (vs ج.م0.05 loss in 2Q 2023) Second quarter 2024 results: ج.م0.17 loss per share (further deteriorated from ج.م0.05 loss in 2Q 2023). Net loss: ج.م8.51m (loss widened 266% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance. Reported Earnings • Jun 08
First quarter 2024 earnings released First quarter 2024 results: ج.م0.02 loss per share. Net loss: ج.م1.02m (loss widened ج.م921.9k from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. New Risk • Mar 30
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (ج.م178.3m market cap, or US$3.76m). New Risk • Aug 17
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Revenue has declined by 61% over the past year. Revenue is less than US$1m (ج.م25m revenue, or US$820k). Market cap is less than US$10m (ج.م212.0m market cap, or US$6.86m). Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ج.م1.12, the stock trades at a trailing P/E ratio of 57.7x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 49% over the past three years. Valuation Update With 7 Day Price Move • Dec 06
Investor sentiment improved over the past week After last week's 25% share price gain to ج.م1.35, the stock trades at a trailing P/E ratio of 69.4x. Average trailing P/E is 4x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 176% over the past three years. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improved over the past week After last week's 416% share price gain to ج.م5.48, the stock trades at a trailing P/E ratio of 56.6x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 1,086% over the past three years. Valuation Update With 7 Day Price Move • Aug 15
Investor sentiment improved over the past week After last week's 18% share price gain to ج.م5.75, the stock trades at a trailing P/E ratio of 69.9x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 170% over the past three years. Reported Earnings • Apr 27
Full year 2021 earnings released: EPS: ج.م0.11 (vs ج.م3.13 in FY 2020) Full year 2021 results: EPS: ج.م0.11 (down from ج.م3.13 in FY 2020). Revenue: ج.م45.4m (down 35% from FY 2020). Net income: ج.م6.78m (down 55% from FY 2020). Profit margin: 15% (down from 22% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment improved over the past week After last week's 88% share price gain to ج.م5.41, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 342% over the past three years. Announcement • Apr 09
Sabaa International Company for Pharmaceutical and Chemical Industry announced that it expects to receive $12 million in funding Sabaa International Company for Pharmaceutical and Chemical Industry (CASE:SIPC) announced a private placement of 6,000,000 common shares at an issue price of EGP 2 per share for gross proceeds of EGP 12,000,000 on April 7, 2021. Pursuant to the transaction, the issued share capital will increase from EGP 88,000,000 to EGP 100,000,000. The transaction has been approved by the Egyptian Financial Regulatory Authority. Valuation Update With 7 Day Price Move • Feb 19
Investor sentiment improved over the past week After last week's 16% share price gain to ج.م8.01, the stock is trading at a trailing P/E ratio of 14.9x, up from the previous P/E ratio of 12.8x. This compares to an average P/E of 7x in the Pharmaceuticals industry in Egypt. Total returns to shareholders over the past three years are 111%. Is New 90 Day High Low • Feb 19
New 90-day high: ج.م8.01 The company is up 18% from its price of ج.م6.78 on 19 November 2020. The Egyptian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period. Valuation Update With 7 Day Price Move • Jan 14
Investor sentiment improved over the past week After last week's 17% share price gain to ج.م6.88, the stock is trading at a trailing P/E ratio of 12.8x, up from the previous P/E ratio of 10.9x. This compares to an average P/E of 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders over the past three years are 32%. Valuation Update With 7 Day Price Move • Nov 17
Market bids up stock over the past week After last week's 20% share price gain to ج.م5.98, the stock is trading at a trailing P/E ratio of 28.6x, up from the previous P/E ratio of 23.9x. This compares to an average P/E of 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders over the past three years are 81%. Is New 90 Day High Low • Oct 26
New 90-day high: ج.م5.20 The company is up 3.0% from its price of ج.م5.05 on 28 July 2020. The Egyptian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.